Overview

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

Status:
Completed

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

This study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN DEVICE can reduce the pain associated with migraine headaches in 30 minutes after use.

Phase:

Phase 3

Details

Lead Sponsor:

Avanir Pharmaceuticals
Optinose US Inc.

Treatments:

Sumatriptan